臨床神経学

<シンポジウム(2)―11―3>アルツハイマー病の新展開―分子病態から治療戦略へ

アルツハイマー病治療に応用可能な抗体の開発

松本 信英1), 金 海峰1), 武田 和也1), 長谷川 由果子1), 本井 ゆみ子1)2), 服部 信孝1)2), 田平 武1)

1)順天堂大学大学院医学研究科認知症診断・予防・治療学講座〔〒113―8421 東京都文京区本郷2―1―1〕
2)順天堂大学医学部神経学講座

Based on the amyloid cascade hypothesis, immunotherapy targeting amyloid β (Aβ) for Alzheimer's disease (AD) has been developed. It was reported that active immunization using Aβ peptide attenuates amyloid deposits and memory impairment in AD model mice. However, active immunization of patients with AD (AN-1792) was halted due to adverse effects in which a subset of patients developed meningoencephalitis. In order to avoid autoimmune encephalitis, passive immunotherapy using humanized monoclonal antibodies with specificity to Aβ are in clinical trials. We also developed an anti-Aβ monoclonal antibody 3.4A10, which react with AD brain-specific Aβ oligomers. On the other hand, some studies showed that immunotherapy approach targeting tau could attenuate pathology in AD model mouse. Here we introduce a current trend of immunotherapy for AD.
Full Text of this Article in Japanese PDF (210K)

(臨床神経, 52:1168−1170, 2012)
key words:アルツハイマー病,ワクチン,抗体,アミロイドβ,タウ

(受付日:2012年5月24日)